Table 1. Comparison of clinical and laboratory features between h-MDS and NH-MDS patients.
| Clinical characters | Total (n=369) | h-MDS (n=100, 27.1%) | NH-MDS (n=269, 72.9%) | P value |
|---|---|---|---|---|
| Sex | 0.324 | |||
| Male | 242 (65.6%) | 70 (70.0%) | 172 (63.9%) | |
| Female | 127 (34.4%) | 30 (30.0%) | 97 (36.1%) | |
| Age (year)* | 65.2 (16.4-94.5) | 61.6 (18.4-94.5) | 65.3 (16.4-90.5) | 0.997 |
| Lab data** | ||||
| WBC (/μL) | 3490 (490-40500) | 3050 (650-9890) | 3660 (490-40500) | 0.030* |
| Hb (g/dL) | 8.1 (3.4-14.6) | 8.1 (3.7-14.4) | 8.2 (3.2-14.6) | 0.971 |
| Platelet (×1,000 /μL) | 77 (3-931) | 66 (3-618) | 82 (3-931) | 0.179 |
| LDH (U/L) | 482 (145-6807) | 463 (145-3122) | 495 (210-6807) | 0.361 |
| PB blast count (/μL) | 0 (0-3270) | 0 (0-523) | 0 (0-3270) | 0.006* |
| BM blast % | 3.2 (0-19.0) | 2.0 (0-19.0) | 4.5 (0-19.5) | 0.001* |
| 2008 WHO classification# | ||||
| RCUD | 75 (20.3%) | 28 (28.0%) | 47 (17.5%) | 0.029* |
| RARS | 20 (5.4%) | 3 (3.0%) | 17 (6.3%) | 0.302 |
| RCMD | 94 (25.5%) | 38 (38.0%) | 56 (20.8%) | 0.001* |
| RCMD-RS | 14 (3.8%) | 3 (3.0%) | 11 (4.1%) | 0.767 |
| RAEB1 | 78 (21.1%) | 11 (11.0%) | 67 (24.9%) | 0.004* |
| RAEB2 | 85 (23.1%) | 17 (17.0%) | 68 (25.3%) | 0.097 |
| MDS-U | 3 (0.8%) | 0 (0%) | 3 (1.1%) | 0.566 |
| IPSS‡#§ | <0.001* | |||
| Low+INT-1 | 219 (64.2%) | 72 (80.0%) | 147 (58.6%) | |
| INT-2+High | 122 (35.8%) | 18 (20.0%) | 104 (41.4%) | |
| IPSS-R‡#ζ | 0.001* | |||
| Very low+low+INT | 197 (57.8%) | 65 (72.2%) | 132 (52.6%) | |
| High+very high | 144 (42.2%) | 25 (27.8%) | 119 (47.4%) | |
| Treatment modalities | ||||
| Transfusion/BCS | 235 (63.7%) | 70 (70.0%) | 165 (61.3%) | 0.144 |
| HMA | 20 (5.4%) | 4 (4.0%) | 16 (5.9%) | 0.608 |
| Intensive chemotherapy | 26 (7.1%) | 2 (2.0%) | 24 (8.9%) | 0.021* |
| Lose-dose chemotherapy | 37 (10.0%) | 7 (7.0%) | 30 (11.2%) | 0.329 |
| HSCT | 51 (13.8%) | 17 (17.0%) | 34 (12.6%) | 0.309 |
Median (range).
Statistically significant if P<0.05.
Number of patients (% of patients within either hypoplastic or non-hypoplastic MDS subgroups).
341patients, including 90 h-MDS and 251 NH-MDS patients, had chromosome data at diagnosis.
IPSS: Low, 0; intermediate (INT)-1, 0.5-1; INT-2, 1.5-2; and High, ≥ 2.5.
IPSS-R: Very low, ≦1.5; Low, >1.5-3; intermediate (INT),>3-4.5; High, >4.5-6; and Vey high, >6.
Abbreviations: h-MDS, hypoplastic MDS; NH-MDS, normo-/hypercellular MDS; FAB, French-American-British classification; RARS, refractory anemia with ring sideroblasts; RAEB, refractory anemia with excess blasts; RCUD, refractory cytopenia with unilineage dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; and MDS-U, MDS (unclassifiable); IPSS, international prognosis scoring system; IPSS-R, revised IPSS.